Delphia Therapeutics is at the forefront of cancer treatment innovation with its pioneering approach known as activation lethality. This next-generation precision medicine strategy targets the unique vulnerability of cancer cells to oncogene overactivation, which can induce lethal cellular stress. Unlike traditional targeted therapies that often lead to resistance mutations, Delphia's platform aims to develop cancer medicines that not only work effectively on their own but also mitigate the emergence of resistance. By focusing on the "undrugged quadrant" of cancer genetics, Delphia is exploring how excessive activation of oncogenic pathways can be leveraged to selectively kill cancer cells, thereby offering a new perspective on cancer biology.

The company employs a multifaceted approach to discover and develop activation lethal targets. This includes utilizing advanced tumor genetics to identify critical pathways susceptible to overactivation, extending functional genomics to gain-of-function studies, and investigating the phenomenon of inhibitor drug resistance. Delphia's strategy involves identifying vulnerable regulators within these pathways that can be targeted to drive overactivation, leading to the selective destruction of tumor cells. By inhibiting these regulators or using allosteric activators, Delphia aims to create a new class of oncology therapeutics that provide durable benefits to patients, reimagining the landscape of cancer treatment.

United States

Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.

Delphia Therapeutics

Company Details